From: Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis
Study (year) Country | Sample size (% female) | Diagnostic criteria used for IBS | Type of IBS (based on the predominant stool form) | Criteria used to define symptom improvement | Moxa intervention (duration)* | Control intervention (duration) | Risk of bias assessmenta |
---|---|---|---|---|---|---|---|
Luo (2012) China [26] | 40 (53%) | Rome III, negative GI investigations and TCM criteria (liver-qi stagnation type) | C 100% | Any improvement in global IBS symptoms | Moxa (4 weeks): Herbal cake-partitioned and individualised, o.d. | Medication (4 weeks): Mosapride 5 mg/time, t.i.d. | U-U-N-N-Y-Y |
Chu (2011) China [20] | 60 (22%) | Rome II and TCM criteria | D 100% | ≥ 30% improvement in global IBS symptoms | Moxa (15 days): Indirect and partially individualised, o.d. | Medication (15 days): Loperamide 2 mg/time, b.d. | Y-U-N-N-Y-Y |
Luo (2011) China [25] | 60 (42%) | Rome III, IBS-C according to Bristol Stool Form Scale, and negative GI investigations | C 100% | ≥ 30% improvement in global IBS symptoms | Moxa (2 weeks): Indirect and fixed, o.d. | Medication (2 weeks): Mosapride 5 mg/time, t.i.d. | U-U-N-N-Y-Y |
Luo (2008) China [27] | 95 (49%) | Rome III, negative GI investigations and Standards for clinical diagnosis for IBS from 1986 National conference for chronic diarrhea | D 100% | Any improvement in global IBS symptoms | Moxa (30 days): Indirect and fixed, b.d., 10 days/course, 3 courses in total | Medication (30 days): Pinaverium, 50 mg/time, t.i.d. | U-U-N-N-Y-Y |
Huang (2007) China [22] | 65 (unspecified) | Rome III, negative GI investigations and TCM criteria | Unspecified | Any improvement in global IBS symptoms | Moxa (4 weeks): Indirect and partially individualized, o.d. | Medication (4 weeks): Trimebutine 0.2 g/time, t.i.d. | U-U-N-N-Y-Y |
Zhang (2007) China [36] | 60 (62%) | Rome II | D 100% | ≥ 30% improvement in global IBS symptoms | Moxa (2 weeks): Ginger-partitioned and fixed, o.d. for 2 weeks | Medication and standard care (2 weeks): | U-U-N-N-Y-Y |
- Standard care such as diet, psychiatric, and anti-diarrheal therapy | |||||||
- Entero-soluble glutamine 0.4 g, t.i.d. or smecta 3 g, t.i.d. or probiotics 630 mg, t.i.d. | |||||||
Ni (2001) China [28] | 56 (63%) | Negative GI investigations and Standards for clinical diagnosis for IBS from 1986 National conference for chronic diarrhea | D 100% | Change of total IBS symptom score (pre-defined) | Moxa (15 days): Indirect and partially individualized, o.d. for 15 days | Medication (15 days): Nifedipinum, 10 mg/time, t.i.d. | U-U-N-N-N-N |
Wu (1996) China [32] | 81 (44%) | Standards for clinical diagnosis for IBS from 1986 National conference for chronic diarrhea and TCM criteria | Unspecified | Any improvement in global IBS symptoms | Moxa (72 days): Herbal cake-partitioned and individualised, o.d., 12 sessions/course, 5 courses in total, with 3 days of no TX interval | Medication (3 months): | U-U-N-N-Y-Y |
- Piperazine 0.2 g/time, t.i.d. | |||||||
- Smecta, 3 g/time, t.i.d. |